RxDoctor Payments Data

Brandy Parker

Family · West Burlington, IANPI 1083168967

Payments from drug & device makers

$967in general payments, 2019–2025

Across 27 payments — averaging $35.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$429
  • Johnson & Johnson$177
  • Novo Nordisk$95
  • AbbVie$76
  • Boehringer Ingelheim$65
  • Sumitomo Pharma America, Inc.$64
  • plus $61 from 3 others

What the payments were for

  • Travel & lodging$16717%
  • Food & beverage$68371%
  • Education$11712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$967 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$91,091
Medicare patients
803
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron188$140,549
GemtesaVibegron187$106,769
Methenamine Hippurate336$22,856
EliquisApixaban55$22,166
OzempicSemaglutide12$20,803
Solifenacin Succinate267$12,503
ElmironPentosan Polysulfate Sodium12$12,237
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,852
Tresiba Flextouch U-100Insulin Degludec20$9,425
Tamsulosin Hcl663$7,672
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$7,550
PremarinEstrogens, Conjugated12$7,313
BelsomraSuvorexant12$6,009
Fiasp FlextouchInsulin Aspart (Niacinamide)13$5,853
Mirabegron ErMirabegron14$4,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$64$106,769187 claims
PfizerEliquis, Premarin$11$29,47967 claims
Novo NordiskOzempic$95$20,80312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in West Burlington

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →